|
Gene expression profiling
of progressive and stable childhood pilocytic astrocytomas
L. Girard, J. D. Minna, T. Chen, G. Tomlinson, D. Bowers
University of Texas Southwestern Medical Center, Dallas, TX
Background. Children with Pilocytic Astrocytomas (PAs), the most common
CNS tumor in childhood, may have either a quiescent or progressive clinical
course.
At present, extent of tumor resection and tumor location are the most important
prognostic factors; biological prognostic factors are unknown.
The identification of new prognostic factors for PAs may have important clinical
and therapeutic implications.
Methods. Ten mcg of purified mRNA was extracted from archival flash
frozen tumor tissue from five completely resected recurrent PAs and six
incompletely resected quiescent PAs.
Samples were hybridized to the Affymetrix GeneChip arrays HG-U133A (22,283 probe
sets) and HG-U133B (22,645 probe sets).
The two arrays together evaluate the expression of 24,698 unique genes.
Images from scanned chips were processed using Affymetrix software GCOS 1.0 to
get the raw signals and p-values for each probe set.
This data was then analyzed using in-house software (MATRIX): Array data were
median-normalized and replicate genes were combined by averaging their
signals.
Samples were then grouped according to tumor recurrence or non-recurrence.
Signals were averaged within each group and then compared (by calculating log
ratios of recurrent vs non-recurrent PAs) and sets of genes showing differential
RNA expression in the two groups were derived.
Unsupervised hierarchical clustering was performed.
Results. 282 genes were found to be overexpressed at least 2-fold in the
subset of progressive PAs compared to the subset of quiescent PAs while 168
genes were found to be underexpressed more than 2-fold.
Hierarchical clustering did not reveal any association between recurrence and
global gene expression.
Conclusions. These preliminary results demonstrate the ability of gene
expression profiling to identify PAs with progressive clinical courses.
Children with PAs with such profiling may benefit from closer monitoring and/or
earlier adjuvant therapy.
Copyright 2004 American Society of Clinical Oncology All rights
reserved worldwide.
Source: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-003756,00.asp
|
